Melanoma Clinical Trials in Michigan

Showing 121-140 of 225 trials

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

NCT03941379

The purpose of this observational research study is to follow participants who have been treated with either bel-sar or received alternate treatment (sham, standard of care therapy, etc.) while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and effectiveness in these subjects. This study will collect information from procedures conducted as part of routine follow-up eye care and cancer care. Additionally, the registry will collect all adverse events, information about pregnancy and symptomatic overdose.

Choroidal MelanomaIndeterminate Lesions of Eye

Aura Biosciences500 participantsStarted Mar 2019

Tucson, Arizona, United States • Los Angeles, California, United States • Palo Alto, California, United States +13 more locations

COMPLETEDPhase 1/283 miles

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

NCT02988817

The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors

Ovarian CancerCervical CancerEndometrial Cancer+5 more

Genmab306 participantsStarted Nov 2016

Phoenix, Arizona, United States • Aurora, Colorado, United States • New Haven, Connecticut, United States +38 more locations

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Melanoma Trials in Other Cities

Safety Study of SEA-CD40 in Cancer Patients

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker

Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)

Other Conditions in Michigan